Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Anyuan Pharmaceutical Technology (Shanghai) Co., Ltd. is a Chinese private company located in Shanghai. The firm develops biological macromolecular drugs. It was founded in 2016. Qiang Li is currently the CEO of the company.

Xuhua (Shanghai) Biological R&D Center Co., Ltd., established on 2001-08-08, Business scope includes research,Development of long-acting genetically engineered drugs,Monoclonal Antibodies for Pharmaceutical Use,Technology transfer of self-developed results,And provide relevant technical advice.[Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

The American Red Cross (ARC), also known as the American National Red Cross, is a humanitarian organization that provides emergency assistance, disaster relief, and education inside the United States. It is the designated U.S. affiliate of the International Federation of Red Cross and Red Crescent Societies. It is the largest single supplier of blood and blood products in the United States, collecting and processing approximately 40 percent of the blood supply and distributing it to about 2,600 hospitals and transfusion centers nationwide. The organization researches and tests to protect the safety of the blood supply. It was among the first to develop and implement testing for many infectious diseases including, HIV, hepatitis B and C viruses, West Nile virus, and Chagas disease. The ARC operates the nationwide hemovigilance program to examine donor and patient adverse reactions. Data from the program is used to enhance blood product quality and safety The ARC serves on key committees of AABB and other blood-related organizations, and works closely with the U.S. Food and Drug Administration (FDA). The American Red Cross was established in 1881 and is headquartered in Washington, District of Columbia with 39 immunohematology reference laboratories nationwide.

Virginia Tech Intellectual Properties, Inc. handles, protects and licenses technologies developed by the faculty, staff and students. It facilitates the licensing of technology to companies, encourages new faculty startup ventures, works with publishers and distributors of software, and supports the transfer of research and knowledge to other universities, research institutes and companies. The company was founded in 1985 and is headquartered in Blacksburg, VA.

Hanmi Science Co., Ltd. engages in the management of its subsidiaries. It is mainly engaged in the manufacturing and selling of pharmaceutical ingredients and intermediates. The company was founded on June 15,1973 and is headquartered in Hwaseong-si, South Korea.

Furen Medicines Group is engaged in pharmaceutical research and development, manufacturing and marketing generic drugs.

Kaifeng Pharmaceutical (Group) Co., Ltd. engages in the manufacture and sale of pharmaceutical products. Its products include injection, tablets, capsules, granules, eye drops, ointments, and pharmaceutical raw materials. The company was founded on May 17, 1949 and is is headquartered in Kaifeng, China.

Established in 1973 in Korea, Hanmi Pharmaceuticals now is one of the top 5 pharmaceutical companies in terms of revenue, and the most R&D focused company with the highest R&D investment for several years. Hanmi has been successful for a few decades with high flexibility, continuously changing its market/development strategy from first generics to IMD & FDC (Incrementally Modified Drug and Fixed Dose Combination) to new drug development including innovative small molecules and biologics. During the period of significant changes, Hanmi made multiple strategic collaboration relationships with multinational companies and biotech companies. Based on the success in 1980s and 1990s, Hanmi started its Chinese operation in 1996 with establishment of Beijing Hanmi. Now, Beijing Hanmi grew as a well-localized and well-settled Chinese company with more than 1,300 staffs including R&D, sales / marketing, and manufacturing experts and significant growth rate higher than 20% every year. Currently, Hanmi and Beijing Hanmi is closely collaborating on various business opportunities and new drug development projects as well as sales and marketing in Chinese territories. As the only Asian company with significant presence both in Korea and China, as the most R&D focused company with number of clinical stage projects with competitiveness, and as the company with open innovation based on multiple development/marketing collaborations, Hanmi is trying to develop and provide differentiated treatment options to patients suffering from various disease.

Part of Sino Biopharmaceutical Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (doing business as Chia Tai-Tianqing Pharmaceutical Co Ltd) is a company headquartered in Lianyungang, China. The firm manufactures pharmaceutical products. It was founded in 1969. Kang Xin Yu is the current CEO of the firm.

CP Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., established on 2013-04-22, Business scope includes licensed projects:pharmaceutical production;Pharmaceutical commissioned production;Drug Wholesale;Drug import and export;Drug retail;Drug internet information service;Production of Class II Medical Devices;Technology Import and Export;Production of Class III Medical Devices;Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Teijin Ltd. engages in the management of its group companies that are involved in the environment and energy, safety and protection, information and electronics, transportation, and healthcare businesses. It operates through the following segments: Materials, Healthcare, and Others. The Materials segment handles the manufacture and sale of polyester, aramid, and carbon fiber products as well as plastic and resin products from polycarbonate resin and polyester film. The Healthcare segment deals with the manufacture and sale of pharmaceuticals and home medical equipment. It also provides home healthcare services. The Others segment offers information technology services. The company was founded by Seita Kumura, Itsuzo Hata, and Naokichi Kaneko on June 17, 1918 and is headquartered in Osaka, Japan.

Chengdu Rongsheng Pharmaceutical Co., Ltd. operates as a plasma-processing company in China. It produces plasma derivatives, such as albumin and intravenous immunoglobulin, and hepatitis B and tetanus immunoglobulins. The company was founded in 1997 and is based in Chengdu, China. Chengdu Rongsheng Pharmaceutical Co., Ltd. operates as a former subsidiary of Chengdu Institute Of Biological Products. As per the transaction announced on June 24, 2008, Chengdu Rongsheng Pharmaceutical Co., Ltd. operates as a subsidiary of Beijing Tiantan Biological Products Co., Ltd..

Part of Pacific Shuanglin Bio-pharmacy Co., Ltd., Guangdong Shuanglin Biological Pharmaceutical Co. Ltd. is a Chinese company. The firm manufactures and distributes pharmaceutical products.

Chengdu Yuanyuan Biotechnology Co., Ltd., established on 2012-10-30, Business scope includes biotechnology research and development,technical consulting(No pre-licensed items,Post-licensing projects operate on the basis of licenses or approval documents);Medical Technology Consulting(No pre-licensed items,Post-licensing projects operate on the basis of licenses or approval documents);Sales of chemical products(Free of Hazardous Chemicals),Computer hardware and software.

Shanghai Tailong Biomedical Technology Co., Ltd., established on 2011-06-21, Business scope includes biopharmaceutical products,Research and development of biochemical products(remove human stem cells,Development and application of genetic diagnosis and treatment technology),Pharmaceutical Intermediates(In addition to drugs),Chemical Products(Removal of hazardous chemicals,Monitor Chemicals,civilian explosives,precursor chemicals)research and development,Sales,And provide relevant technical consultation and technical services,Equipment,Electronic product development,Sales,account Serive. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Bayer HealthCare Ltd., established on 1995-08-25, Business scope includes licensed projects:pharmaceutical production;Pharmaceutical commissioned production;Drug Wholesale;Drug import and export;Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;food sales;Health food production;food production;Production of formula food for special medical purpose;Cosmetic production;Production of hygiene products and single-use medical products;Disinfectant production(Free of Hazardous Chemicals).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Cosmetics Wholesale;Cosmetics Retail;internet sales(Except for products that require a license for sale);Food import and export;software development;software sales;Retailing of computer software, hardware and auxiliary equipment;Wholesale of computer software, hardware and auxiliary equipment;Manufacturing of computer software, hardware and peripheral equipment;Software outsourcing service;Information Consulting Service(Not including licensing information consulting services);Information Technology Consulting Services;Special Equipment Repair;Import and export;Technology Import and Export;Import and export agency;Sales of hygiene products and single-use medical products;Disinfectant sales(Free of Hazardous Chemicals);Manufacturing of daily chemical products;Sales of daily chemical products.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)(Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

China Resources Boya Bio-pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of blood products. It operates through the following business segments: Blood Products, Diabetes Medication, and Biochemical drugs. The Blood Products segment includes products such as albumin, immunoglobulin, and blood clotting factors. The Diabetes Medication segment includes metformin hydrochloride tablets, enteric-coated tablets, and calcium hydroxybenzenesulfonate capsules. The Biochemical Drugs segment includes medication such as compound bone peptide injections, oxytocin injections, and heparin sodium injections. The company was founded on November 6, 1993 and is headquartered in Fuzhou, China.

Shanghai Zhouyue Biotechnology Co., Ltd., established on 2014-09-19, Business scope includes technology development in the field of biotechnology,technical consulting,technology transfer,Technical Services. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

The Chemo-Sero Therapeutic Research Institute operates as a pharmaceutical company specializing in the field of biotechnology, immunology, hematology, and microbiology. It develops and manufactures vaccines and blood plasma products. The firm's products include human and veterinary vaccines, diagnostic antigens, and treatments for congenital disorders. They also provides newborn screening tests and quality assurance systems solutions. The company was founded on December 26, 1945 and is headquartered in Kumamoto, Japan.